Pediatric ovarian neoplastic tumors: incidence, age at presentation, tumor markers and outcome.

Acta Obstet Gynecol Scand

Department of Pediatric Surgery, Children's Hospital, University of Helsinki, Helsinki, Finland.

Published: April 2015

Objective: To investigate the incidence, age of onset and tumor marker levels in benign and malignant pediatric ovarian neoplastic tumors.

Design: Retrospective database study.

Setting: Single-center study.

Population: Forty-five 0-15-year-old girls operated on for ovarian neoplastic tumors from the beginning of 1999 to the end of 2013.

Methods: Serum alpha-fetoprotein, human chorionic gonadotropin and CA 125 levels as well as follow-up data were recorded from patient charts and tumor histology was re-evaluated.

Main Outcome Measures: Incidence of ovarian neoplastic tumors in the pediatric population. Differences in patient characteristics and tumor marker levels between those with benign and malignant tumors.

Results: The annual incidence of ovarian tumors was 2.2/100,000 females. Median age at presentation was 13.0 years (range 0.9-15.7), similar in both the 33 (73%) girls with a benign tumor and the 12 (27%) girls with a malignant tumor. The tumors with the highest propensity to metastasize (yolk sac tumors, mixed germ cell tumors, small cell carcinoma) were only found in girls > 9 years. Elevated serum alpha-fetoprotein and CA 125 values associated more often with malignant tumors (p < 0.001 and p < 0.031, respectively). There were no deaths or local recurrences. Four girls with a mature teratoma developed a contralateral benign ovarian tumor during follow up.

Conclusions: Both benign and malignant ovarian tumors are rare in the pediatric population, but the incidence increases with age. High alpha-fetoprotein and CA 125 levels were associated with malignant tumors. The prognosis of the pediatric ovarian tumors seems to be favorable.

Download full-text PDF

Source
http://dx.doi.org/10.1111/aogs.12598DOI Listing

Publication Analysis

Top Keywords

ovarian neoplastic
16
pediatric ovarian
12
neoplastic tumors
12
benign malignant
12
ovarian tumors
12
tumors
11
incidence age
8
age presentation
8
tumor marker
8
marker levels
8

Similar Publications

Ovarian cancer is the seventh most common lethal tumor among women in the world. FOXM1 is a transcription factor implicated in the initiation and progression of ovarian cancer by regulating key oncogenic genes. The role of regulatory regions in regulating the expression of FOXM1 in ovarian cancer is not completely clarified.

View Article and Find Full Text PDF

TWIST1 Regulates FOXM1/β-Catenin to Promote the Growth, Migration, and Invasion of Ovarian Cancer Cells by Activating MFAP2.

J Biochem Mol Toxicol

February 2025

Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.

TWIST1 is aberrantly expressed in ovarian cancer (OC). MFAP2 is a downstream target of TWIST1, and we previously found MFAP2 facilitated OC development by activating FOXM1/β-catenin. We planned to investigate the mechanisms of TWIST1 in OC.

View Article and Find Full Text PDF

Unusual presentation of an aggressive ovarian malignancy in a young pregnant woman.

BMJ Case Rep

January 2025

Obstetrics and Gynaecology, NHS Ayrshire and Arran, Ayr, South Ayrshire, UK.

Cancer during pregnancy is uncommon. Symptoms caused by new cancers in pregnancy can be difficult to recognise leading to a delay in diagnosis and treatment. Ovarian cancer during pregnancy poses a further diagnostic challenge due to the vague symptoms that it can present, along with difficulty in the interpretation of tumour markers.

View Article and Find Full Text PDF

piR-26441 inhibits mitochondrial oxidative phosphorylation and tumorigenesis in ovarian cancer through m6A modification by interacting with YTHDC1.

Cell Death Dis

January 2025

Department of Obstetrics and Gynecology, Department of Gynecologic Oncology Research Office; Guangzhou Key Laboratory of Targeted Therapy for Gynecologic Oncology; Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology; Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine; The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

Ovarian cancer (OC) is a heterogeneous cancer. In contrast to other tumor cells, which rely primarily on aerobic glycolysis (Warburg effect) as their energy source, oxidative phosphorylation (OXPHOS) is also one of its major metabolic modes. Piwi-interacting RNAs (piRNAs) play a regulatory function in various biological processes in tumor cells.

View Article and Find Full Text PDF

LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance.

Cancer Metastasis Rev

January 2025

Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, 5005, Australia.

Cancer stem cells play an important role in tumor progression and chemotherapy resistance. Leucine-rich G repeat-containing protein-coupled receptor 5 (LGR5) has been identified as a cancer stem cell marker in several cancer types. LGR5 is involved in cancer development and progression via several pathways including WNT/β-catenin signaling pathway.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!